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With 390million people infected every year, dengue is now a global
concern [1]. Over the past decades, the virus has spread from South East
Asia to regions across the world with climates favorable for breeding of
the transmitting vector, the Aedes or “tiger” mosquito. In Singapore,
where this studywas conducted, dengue is endemic and approximately
half the adult population is seropositive, providing an excellent oppor-
tunity to compare primary and secondary (memory) responses. The
dengue virus (DENV) complex comprises four antigenically related vi-
ruses (DENV-1 to 4) from the ﬂavivirus family, and infection with one
serotype generates both serotype-speciﬁc and cross-reactive antibodies
[2]. During heterotypic re-infection, the antibody response is dominated
by cross-reactive antibodies binding to regions in the viral proteins that
are conserved across all serotypes [3,4]. At the same time, neutralizing
antibodies against the serotype of the previous infection are often am-
pliﬁed more efﬁciently than antibodies against the new infecting sero-
type, which can result in increased disease severity when an
individual is re-infectedwith a different serotype, a phenomenon previ-
ously described as original antigenic sin [5,6].etwork, 8A Biomedical Grove,
Fink).
polis Cedex, France.
. This is an open access article underB cell activation, including the activation of pre-existing memory B
cells (MBC), contributes to a substantial plasmablast response during
acute heterologous infection [7–9], resulting in a high increase in neu-
tralizing antibody titers [10] that contribute to temporary cross-protec-
tion against all four serotypes. Recently, we demonstrated that this
plasmablast response is polyclonal, but all antibodies cloned from the
genes of individual plasmablasts recognized the envelope (E) glycopro-
tein. In contrast, the majority of previously reported DENV-speciﬁc
MBCs isolated from the blood of recovered dengue patients were specif-
ic to either prM, a membrane protein expressed on immature, non-in-
fectious virus particles, or to non-structural proteins, notably NS1 [11–
14], potentially indicating separate pathways of development between
plasmablasts and classical MBCs.
The establishment of multiple levels of B cell memory has been sug-
gested previously in mice. It was observed that IgM+ germinal center
(GC) derived MBCs re-entered GC reactions upon re-infection, whereas
IgG+ GC-derivedMBCs almost exclusive differentiated into plasmablast
[15]. Another elegant study in wild-type mice documented the genera-
tion of two distinct memory populations after immunization with the
model antigen phycoerythrin: a long-lasting IgM memory population
and amore short-lived IgGmemory population. Upon re-immunization,
switchedmemory cells differentiated into plasmablasts and proliferated
to increase the memory B cell pool without further afﬁnity maturation
[16]. In contrast, the response of IgMmemory B cells after re-immuniza-
tionwas inhibited by high amounts of speciﬁc IgG in the serummasking
the antigen [16]. In B cell receptor (BCR)-transgenicmice, the formationthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
DENV-speciﬁc IgG in the plasma of patients detected by Western blot.
Early Acute Convalescent
Patient number Patient ID Infection Current serotype of infection Time WB Time WB Time WB
1 10/63' Secondary DENV-2 45 h – 4d – 19d –
2 10/50' Secondary DENV-3 17 h – 6d Env, prM 16d Env, prM, NS1
3 E1392 Secondary DENV-2 57 h Env 3d Env, prM 22d Env, prM, NS1
4 E1183 Secondary DENV-2 69 h Env 4d Env, prM 24d Env, prM, NS1
5 E1407 Secondary DENV-2 55 h Env, prM 3d Env, prM 16d Env, prM, NS1
6 E1311 Secondary* DENV-2 14 h nd 7d nd 15d nd
7 C07 Secondary DENV-2 – – 6d Env, prM, NS1 128d Env, prM, NS1
8 E1291 Secondary DENV-2 71 h – 4d Env, prM 23d Env, prM, NS1
9 E1385 Primary DENV-2 16 h – 6d nd 16d Env, prM
10 C01 Primary DENV-2 – – 5d nd 166d Env, NS1
11 E1414 Primary DENV-2 68 h – 4d Env, prM 17d Env, prM, NS1
12 E1465 Primary DENV-2 67 h – 8d nd 33d nd
(–) Serum not available.
(nd) Not detected with 1:1000 dilution of plasma.
(') 10/63 and 10/50 have been described before in Ref. [8].
(*) This patient had no pre-existing DENV-binding IgG and was classiﬁed as secondary due to the highly EDIII-speciﬁc response of the plasmablasts.
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[18], a high antigen-to-B cell ratio, and a strong BCR signal [19,20], but
this system is limited in that only one epitope can be studied. During a
natural viral infection, B cells respond tomultiple viral epitopes, and an-
tibodies with both high and low neutralizing capacities can have similar
afﬁnities [21]. Thus, afﬁnity alone does not determine the efﬁcacy of an
anti-viral response, and the different biological functions of
plasmablasts versus memory B cells and long-lived plasma cells post
primary infection are not clear.
In humans, plasmablasts appear in the blood ﬁve to seven days after
infection or vaccination. Human plasmablasts have been studied exten-
sively tomonitor vaccine- or natural infection-induced speciﬁc B cell re-
sponses and to generate disease-speciﬁc humanmonoclonal antibodies
[8,22–26]. Moreover, the plasmablast response was reported to be pre-
dictive of antibody titers at least during early convalescence [22,24].
Lavinder et al. studied whether plasmablasts or MBCs contributed to
the serum antibody pool after tetanus vaccination and found little rep-
ertoire overlap, concluding that only a small fraction of plasmablasts
and MBCs contributed to long-lived humoral immune memory [27].14-71 h 
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2. Methods
2.1. Patients
The study was approved by the Institutional Review Board of Singa-
pore National Healthcare Group Ethical Domain (DSRB B/05/013), and
patients gavewritten informed consent. Adult patients (age N 21 y) pre-
senting at community primary care clinics with acute-onset fever (N
38.5 °C for 72 h) without rhinitis or clinically obvious alternative diag-
noses were included in the study. Whole-blood samples were collected
into EDTA-vacutainer tubes (Becton Dickinson) at recruitment (acute
phase), at 3–7 d (defervescence), and at 3–4 wk. after fever onset (con-
valescence). Patients were diagnosed by DENV-speciﬁc RT-PCR. DENV-15-166 days
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Fig. 2. B cell repertoires change between acute phase and early convalescence. A and B)
Flow cytometry plots representative of a dengue patient (Patient 3) to illustrate the
sorting strategy. A) Sorting of CD19+, CD20−, CD27hi, CD38hi plasmablasts. B) Sorting of
CD19+, CD20+, CD27+ DENV-binding memory B cells (MBC) (indicated in blue
squares) and non-DENV-binding MBCs (indicated in green square). Sequences from
DENV-2 and DENV-3-binding MBCs were pooled as “DENV-binding MBCs”. C) VH gene
family usage of plasmablasts (PB), DENV-binding MBCs, and non DENV-binding MBCs.
The total numbers of unique CDR3 sequences per sample is indicated in the center of pie
charts. Analysis included IgG sequences, IgM sequences or total sequences, as indicated
next to the charts. Cells from patients 3 and 8 were analyzed with 454 sequencing; for
all other patients, single B cells were analyzed by Sanger sequencing. A Wilcoxon
matched-pairs signed rank test showed a statistically signiﬁcant difference only for VH3
and VH4 usage between PB and MBC-neg cells (p= 0.03).
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available Panbio kits (Inverness Medical, Queensland, Australia). All
twelve patients described in this study were classiﬁed as having prima-
ry or secondary infections based onDENV-speciﬁc serum IgG antibodies
at time of fever onset (Table 1).
2.2. Single-Cell Sorting
Fresh or thawed PBMCs were labeled with antibodies against CD20,
CD27, CD19 (BioLegend), CD38, and CD138 (BD Pharmingen). Dengue-
speciﬁc memory B cells were identiﬁed based on their capacity to bind
to Alexa Fluor 594-labeled DENV-1, Alexa Fluor 488-labeled DENV-2,
and Alexa Fluor 647-labeled DENV-3. Live virus particles were labeled
(Protein Labeling Kit from Molecular Probes) and inactivated with
DEPC [29]. PBMCs were stained and resuspended in sorting buffer
(PBS, 2% FCS, 2 mM EDTA) for sorting into 96-well PCR plates using a
FACSAria (BD). The plates contained 10 mM Tris-HCL with 40 U/μl
RNase inhibitor (Promega), 10 μl per well. Plates were placed on dry
ice immediately after sorting and stored at−80 °C.
2.3. Ig Cloning, Expression, and Puriﬁcation
The mRNA of human IgG and IgM heavy and light chains was ampli-
ﬁed from single B cells as described previously [26], using modiﬁed
primer sets for RT-PCR (Table S1). One-step RT-PCR (OneStep RT-PCR
Kit, Qiagen) was performed using forward primers in the heavy and
light chain leader sequence and reverse primers in the constant region
of IgG, IgM, kappa, or lambda. Reported primers were used for the
nested IgM and IgG PCR [26] for cloning into expression vectors, RT-
PCR products were used for nested IgG-PCR with modiﬁed primers
(Table S1): SalI and NheI sites were added at the 5′ and 3′ ends of the
H chain, and SalI and BbvCI/NotI sites were added at the 5′ and 3′ end
of the kappa or lambda light chains, respectively. The PCR products
were cloned into the Ptt5 mammalian expression vector [30] (licensed
from the National Research Council Biotechnology Research Institute,
Montreal, QC, Canada). Heavy and light chain plasmids (IgG1 format)
were co-transfected into the HEK293-6E cells using 293-Transfectin
(Invitrogen). Transfected 293-6E cells were allowed to secrete antibod-
ies in serum-free F17media supplementedwith 20% TN1 for 5 days. An-
tibodies were puriﬁed using protein G beads (GE Healthcare).
2.4. Ig Gene Sequencing
The PCR products of the heavy and light chain variable regions from
single B cells were sequenced by Sanger sequencing. The quality of the
sequences was checked with CodonCode Aligner software, sequences
were trimmed and further analyzed using the IMGT database [31]
(http://www.imgt.org/). For 454 sequencing, immune repertoire
cDNA libraries were prepared using the Human BCR heavy chain
primers (iRepertoire Inc., Huntsville, AL, USA) covering the V and C re-
gions. In brief, 1 ng of total RNA isolated from sorted cells was reverse
transcribed and ampliﬁed using Qiagen One-Step RT-PCR kit. The reac-
tion mix for the ﬁrst round of ampliﬁcation contains a pool of primers
targeting the V region and reverse primers that add barcodes for
demultiplexing [32]. Secondary PCR was carried out to further enrich
for heavy chain sequences using a Qiagen Multiplex PCR Kit and the
iRepertoire® 454 Lib-A primers, according to the instructions described
in iRepertoire® manual. Ampliﬁed PCR products were electrophoresed
using a 2% agarose gel, and PCR fragments in the size range of 300–
475 bpwere gel-puriﬁed using theQiaquickGel Extraction Kit (Qiagen).
The puriﬁed fragments were quantiﬁed using the Quant-iT ™
Picogreen®dsDNAAssay kit (Invitrogen) and submitted for sequencing
(Macrogen Inc., Seoul, South Korea). Each of the patient samples were
sequenced using the GS-FLX Titanium454 platform (Roche, Mannheim,
Germany) to generate 400 bp single end reads at a depth of 250,000 se-
quences per sample.
181R. Appanna et al. / EBioMedicine 12 (2016) 178–1882.5. Sequence Processing and Analysis
454 sequences with a minimum length of 250 bases were uploaded
to IMGT/HighV-QUEST v1.5.1. The output list was ﬁltered by removing
‘unproductive’ and ‘unknown’ sequences. Sequences with a potential
insertion/deletion, low V region identity (b84.98%) compared to
germline sequences, and sequences with missing Cys 104 were further
removed before analysis of the remaining sequences in MiXCR [33].
These sequences were saved in FASTA format to use as input for
MiXCR (version 1.8.2) [33]; applying presets to optimize the analysis
of RNA-Seq data, MiXCR aligned the sequences to reference V, D, J and
C genes of B-cell receptors; using these alignments we extracted full
CDR3 sequences, discarding those backed up by just one mapped read
from further analyses. For each patient and cell type, V gene usage and
isotype (C gene) information was extracted from MiXCR results,
selecting the best hit(s) according to alignment scores. Individual
CDR3s were grouped together into clones, deﬁned here as a group of
CDR3s with the same V, D and J gene usage, with the same length and
sharing at least an 85% sequence identity [34]. R (version 3.3.1) was
used to perform global pairwise alignments between all the possible
unique permutations of CDR3s with the same VDJ combination and
length, and construct a distance matrix with 100% sequence ID as the
distance measure; single linkage hierarchical clustering was applied,
cutting the tree at height equal to 15% sequence dissimilarity to
deﬁne the clones. Both individual CDR3 and CDR3 clone appearance
across cell types within a patient was studied, and Venn diagrams
were drawn (see Fig. 2A,D). A clone is considered to appear in two
different cell types when at least one of the CDR3s in one cell type
shares at least an 85% sequence identity with at least one CDR3 in the
other cell type. Mutation analysis in Fig. 2E was done using the
IMGTJunctionAnalysis tool [35].
2.6. Cell Lines, Virus Strains and Virus Production
Viruswas produced in C6/36mosquito cells (American Type Culture
Collection). The following patient-isolate strains were precipitated
using polyethyleneglycol (PEG) and were resuspended in NaCl-Tris-
EDTA buffer for use in the ELISA: DENV-1 08K3126 (unpublished geno-
type I strain isolated by the Environmental Health Institute, Singapore),
DENV2-TSV01 (AY037116.1), DENV3-VN32/96 (EU482459), and
DENV4-2641Y08 (HQ875339.1).
2.7. Western Blot
C6/36 cells were seeded in a 75 cm2 ﬂask and were infected with
DENV-1 08 K3126, DENV2-TSV01, DENV3-VN32/96, or DENV4-
2641Y08 at a multiplicity of infection (MOI) of 1 when they reached
70–80% conﬂuence. Culture medium was removed 24 h after infection
and cellswerewashed twicewith cold PBS before lysis in cold RIPA Buff-
er containing protease inhibitors (Complete, Roche). Lysates were col-
lected and centrifuged at 14,000 g for 15 min to pellet the cell debris.
The supernatants containing viral proteins were collected and stored
at−20 °C. Cleared lysates were heated at 95 °C for 5 min in non-reduc-
ing Laemmli buffer prior to separation by SDS-PAGE (NuPAGE 4–12%
Bis-Tris Gel: Invitrogen) and electro-transfer to PVDF membranes
(Hybond-P; Amersham, GE Healthcare). The membranes were incubat-
ed with recombinant antibodies or with a pool of plasma from dengue-
immune healthy donors (1:20,000), followed by peroxidase conjugated
goat anti-human IgG (1:10,000; Jackson ImmunoResearch).
2.8. ELISA
DENV-speciﬁc ELISAs were performed by coating high-binding 96-
well plates overnight with PEG-precipitated DENV serotypes 1–4 or
with recombinant E proteins generated in S2 cells as described previ-
ously [10]. Plates were blocked with PBS, 0.05% Tween 20, and 3%skim milk. Supernatants from Ab-expressing HEK cells were incubated
on virus-coated plates for 1 h at room temperature before washing
with PBS 0.05% Tween 20 and detection with a secondary anti-human
IgG-HRP (Sigma). To determine the absolute concentration of IgG,
plates were coated with anti-Ig Ab (Caltag). Different concentrations
of an IgG standard were included to generate a standard curve and
pooled serum from dengue-immune healthy donors was used as a pos-
itive control. TMB substrate solution (Sigma)was used for all ELISAs. An
OD value at least 2-fold higher than the background was deﬁned as a
positive signal.
2.9. Virus Neutralization Assay
U937 cells expressing DC-SIGN were seeded overnight on 96-well
plates [10]. A six point dilution series of protein G–puriﬁed mAbs dilut-
ed in RPMI 1640 medium without FCS were incubated with a constant
amount of DENV-1 05K2916 (EU081234), DENV-2 TSV01, DENV-3
VN32/96, or DENV-4 2641Y08 at anMOI of 1 for 30min at 37 °C. Plasma
or mAb–virus mixtures were then transferred onto the U937-DC-SIGN
cells and incubated for 2 h at 37 °C before adding RPMI 1640, 10% FCS.
After incubation overnight, cells were stained intracellularly with Abs
against NS1 and E protein and analyzed on a FACSVerse cytometer
(Becton Dickinson). Data were analyzed using FlowJo software
(TreeStar). The proportions of infected cells were plotted against the di-
lution factor, and the EC50 was calculated with Prism5 (GraphPad Soft-
ware), applying a three-parameter non-linear curve ﬁt.
2.10. Immunohistochemistry
BHK-21 cells were seeded in 96-well plates and infectedwith DENV-
1 08K3126, DENV-2 TSV01, DENV-3 VN 32/96, or DENV-4 2641Y08.
After 48 h, the cells were ﬁxed with 4% paraformaldehyde for 20 min
at room temperature. For intracellular staining, cells were perme-
abilized with PBS/0.1% Triton X-100 for 15 min at room temperature.
Cells were then washed and blocked with 1% BSA in PBS for 2 h at
room temperature. Fixed cells were incubated with primary antibodies
at a concentration of 1 μg/ml at room temperature for 1 h, followed by
Alexa Fluor 488 goat anti-human IgG (Invitrogen) 1:2000 at room tem-
perature for 1 h. Nuclei were counterstained with Hoechst (Invitrogen)
for 5 min (1:15,000 in PBS). Stained cells were visualized using a confo-
cal microscope (OLYMPUS).
3. Results
3.1. Antibody Variable Region Gene Usage Differs between Plasmablasts
and Memory B Cell from Longitudinal DENV Patients Samples
To study the evolution of the B cell repertoire during DENV infection,
blood samples from twelve patients infected with DENV virus serotype
2 (eleven patients) or serotype 3 (one patient) were collected during
acute disease and after recovery. The study timepoints and analysis per-
formed are summarized in Fig. 1. In a primary infection, DENV-speciﬁc
IgG can only be detected ﬁve to seven days after fever onset. Therefore,
to distinguish between patients with pre-existing DENV immunity and
those without previous exposure to the virus, DENV-speciﬁc IgG anti-
bodies weremeasured by ELISAwithin 72 h of fever onset. This analysis
identiﬁed eight patients with secondary infections and four patients
with primary infections (Table 1). Plasmablasts (PB; CD19+ CD20−
CD27high CD38high cells) were sorted from peripheral blood of patients
with secondary infection three to seven days after fever onset (see
Fig.2A and Supplementary Fig.1A online for detailed sorting strategy).
Speciﬁc and non-speciﬁc memory B cells (MBCs; CD19+ CD20+
CD27+ CD38low cells) were sorted 16 to 25 days after fever onset
using ﬂuorescently labeled virus to distinguish between DENV-binding
and non-binding cells (DENV+ or – cells), respectively (Fig. 2B and Sup-
plementary Fig. 1B online). The DENV serotypes used for MBC sorting
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183R. Appanna et al. / EBioMedicine 12 (2016) 178–188are listed in Table S2. After analyzing the ﬁrst two patients we noticed
that almost all MBCs were serotype cross-reactive regardless of the
virus used for sorting. For the subsequent secondary patients we used
the DENV-3 probe, which showed the highest % of binding cells. Very
few MBCs bound to DENV-1 and this population was therefore not fur-
ther analyzed. Across all patients analyzed in this study 0.1–19% of total
lymphocytes were activated as plasmablasts and 0.5–8.1% of
CD19+CD20+ B cells bound to DENV (Table S3). Cells were sorted
into 96-well plates for PCR-ampliﬁcation of single cell heavy chain var-
iable region (IgVH) and light chain variable region (IgVL) transcripts,
with the exception of cells from patients 8, 11 and 12, which were ana-
lyzed by 454 sequencing [32]. For patient 3, both single cell and 454 se-
quencing were carried out (Fig. 1). To address potential repertoire
differences we compared IgVH V and J gene usage in plasmablasts,
DENV-binding and non-binding MBCs in patients with secondary infec-
tions (Fig. 2C). VH usage of plasmablasts compared to DENV-binding
MBCswas not signiﬁcantly different, possibly due to the limited number
of sequences analyzed per patient. Therewas a signiﬁcant difference be-
tween VH3 and VH4 usage in plasmablasts compared to non-binding
MBCs (p = 0.03). The primers used for single cell PCR ampliﬁcation
and for deep sequencing bind in the constant region, preserving infor-
mation about variable region and isotype (Fig.2C). There seemed to be
more pronounced differences in VH usage between plasmablasts and
DENV-binding MBCs when the IgG-, IgM- and IgA-expressing cells
were analyzed separately (Supplementary Fig. 2A). However, only the
two secondary patients analyzed with 454 sequencing had sufﬁcient
numbers of sequences per isotype for a separate analysis and a statistical
test could not be done. Higher VH1 gene usage in plasmablasts com-
pared with MBCs, as we reported previously [8], was only observed in
three out of ﬁve patients here, indicating that high VH1 usage in
plasmablasts is not universal in DENV infection. Typically, infections
such as inﬂuenza results in a large clonal expansion of individual B
cells [36,37], however only patient 6 displayed a large clonal expansion,
whereas the remainingdonors showed polyclonal activation and little or
no clonal expansion in the plasmablast population (Supplementary Fig.
2B online and [8]). The expanded clone in patient 6 was an IgG clone
and the respective antibodies bound speciﬁcally to EDIII of DENV-1,
even though the patientwas infectedwith DENV-2. Thismight be an ex-
ceptional case for which we don't have an explanation yet.
3.2. No Evidence that Acute Disease B Cell Sequences Are clonally Expanded
in the Memory Pool
Since VH and JH gene family usage seemed to differ between acute
and convalescent time points (Fig. 2C and Supplementary Fig. 2A) we
tested whether plasmablast and MBCs were clonally related. Pools of
longitudinal plasmablasts and memory B cell repertoires analyzed by
454 sequencing were used for this comparison (Fig. 3). We found that
only few CDR3 sequences were shared between plasmablasts and
early convalescence DENV-2 or−3 binding memory B cells from the
same individual infected with DENV-2 (Fig. 3A). In addition, no
plasmablast sequences were found in the DENV-3 binding MBC reper-
toire that was isolated and deep sequenced one year after infection for
patient 2 who was infected with DENV-3 (data not shown).
Since repertoires during secondary infection are biased towards
cross-reactive and afﬁnity- matured cells we also included two patients
with primary infection in the analysis (patients 11 and 12) but found
similarly low numbers of CDR3s shared between plasmablasts andFig. 3. Few shared sequences between plasmablasts andmemory B cells. A) Identical unique CDR
non-binding MBCs (MBC-neg) for two patients with secondary DENV-2 infection (E1291, E139
reads for sequences shared between PBsMBC-DENV andMBC-neg. C) number ofmapped reads
memory compartment. D) Shared clones based on at least 85% identity in the CDR3 amino acid s
in theMBC-DENV repertoire. TheMBC-DENVCDR3 sequence in bold in the x-axis represents the
andmutation is indicated above the graphs, with bold characters indicating the dominant seque
was used for the analysis.dengue-binding MBCs (MBC-DENV) (Fig. 3A). If B cell clones that partic-
ipate in the plasmablast response are also retained in the memory pool
we would expect a speciﬁc expansion of the respective MBC-DENV
clones. Overall, 61 CDR3s were found in more than one subset and
were either expanded in PB or the MBC pools (Fig. 3B). Eight CDR3 se-
quences from two out of four patients were at least ten times expanded
(in terms of mapped reads) in the DENV-speciﬁc memory compartment
compared to the plasmablast compartment (Fig. 3C). To account for af-
ﬁnity maturation between acute and early convalescence phase we
next collapsed CDR3 amino acid sequences that were at least 85% identi-
cal into clones for each cell population [38]. Similar to the analysis of
identical CDR3 sequences, few related CDR3 clones were found in both
plasmablasts and MBC-DENV in the same individual (Fig. 3D). This was
true both in the case where the DENV serotype of the recent infection
or a heterologous serotype was used for MBC sorting (Supplementary
Table S1). Only three out of eight shared clones were mutated in MBC-
DENV compared to plasmablasts but the amino acid mutations were
found in the non-expanded MBC-DENV CDR3s (Fig. 3E). Surprisingly,
the MBC-DENV expanded clones contained exclusively IgM sequences
(Fig. 3C and E). In fact, a large fraction of DENV-speciﬁc memory B cells
expressed IgM, compared to plasmablasts, which were dominated by
IgG-expressing cells in both primary and secondary infection cases and
compared to non-DENV binding MBCs, which predominantly expressed
IgG (Fig. 2F).We assume that a signiﬁcant number of B cells in themem-
ory IgM repertoire bind to DENV with relatively low afﬁnity and that
these cells were enriched during the MBC sorting. In fact, we also ob-
served DENV binding in two non-dengue immune individuals (Fig. S1C).
Overall, the majority of clones activated during the acute phase in
the plasmablast response were not represented in the circulating MBC
repertoire at convalescence and there was no evidence of speciﬁc ex-
pansion or afﬁnity maturation for the related MBC-DENV clones.
3.3. Plasmablast-Derived mAbs Are E Protein-Speciﬁc whereas MBC-De-
rived mAbs Bind to a Wider Range of Viral Antigens
Wenext testedwhether the different VDJ gene usage of plasmablasts
andmemory B cells resulted in different B cell speciﬁcities.We previous-
ly reported that plasmablasts were predominantly E protein-speciﬁc,
but did not analyze the speciﬁcity of the memory B cells in that study
[8]. Others have shown that more than half of DENV-speciﬁc memory
B cells were speciﬁc to prM and to non-structural (NS) proteins [11–
14]. We ﬁrst analyzed the speciﬁcity of Abs in plasma collected from pa-
tients within 72 h of fever onset, during acute disease (day 3–8), and at
convalescence (day 15–166) by western blot (Table 1). Antibodies to
prM, E, were detectable during acute disease in six out of seven patients
with a secondary infection, whereas NS1-speciﬁc Abs were mostly ob-
served during convalescence. Hence, prM -speciﬁc antibody-secreting
cells were generated or mobilized during acute disease, but they did
not seem to participate in the plasmablast response, which only
contained E-speciﬁcmAbs, consistent with our previous observation [8].
To further explore B cell population-associated differences in speci-
ﬁcity, recombinant monoclonal antibodies (mAb) were cloned and
expressed from the IgG-expressing plasmablasts and -MBCs, isolated
longitudinally from individuals during acute disease and at convales-
cence. Speciﬁcity of themAbs to E protein, E domain III (EDIII, the bind-
ing site of potent neutralizing antibodies to E protein), and to prM, was
determined as described in Fig. 4A. On average, 64% of the mAbs cloned
fromplasmablasts and 52% of themAbs cloned from sortedMBCs bound3 Sequences shared between plasmablasts (PB), DENV-2-bindingMBCs (MBC-DENV) and
2) and two patients with primary DENV-2 infection E1414, E1465. B) Numbers of mapped
and isotype for PB andMBC-DENV shared sequences that are at least 10× expanded in the
equence. E) CDR3mutation analysis for the three clones thatwere expanded andmutated
expanded clone according to thenumber ofmapped reads. TheCDR3 amino acid sequence
nce. F) Isotype distribution of PB,MBC-DENV andMBC-neg sequences. Totalmapped reads
184 R. Appanna et al. / EBioMedicine 12 (2016) 178–188to DENV (Fig. 4B). Of the DENV-speciﬁc mAbs derived from
plasmablasts (75 unique sequences from 7 patients), 85.3% recognized
recombinant E protein compared with only 17.8% of the DENV-speciﬁcA
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background)mAb derived from MBCs (45 unique sequences from 4 patients), (Fig.
4C), conﬁrming again the dominance of E protein-speciﬁc Abs during
acute infection. Antibodies to prM were not detected in the
plasmablasts, but accounted for 24.4% of those in the MBC population
(Fig. 4C). Antibodies that bound intact virus particles in ELISA or from
infected cell lines, as determined by immunohistochemistry, but did
not recognize E or PrM proteins were designated as complex epitope-
speciﬁc mAbs. 14.7% of plasmablast-derived mAbs compared with
55.6% of MBC-derived mAbs (Fig. 4C).
Recent studies have suggested that Abs binding to intact virus parti-
cles but not to recombinant E protein, i.e., the complex epitope-speciﬁc
mAbs described here, can be potent neutralizers [2,12,39–42]. To test
the relative neutralizing capacities of complex epitope-speciﬁc mAbs
and E protein-speciﬁc Abs, we compared their 50% neutralizing titer
(NT50) using human U937 monocytic cells stably transfected with the
DENVbinding receptor DC-SIGN [2]. E protein-speciﬁcmAbswere capa-
ble of neutralizing the three serotypes tested at lower concentrations
(0.1–10 μg/ml) compared with the complex epitope-speciﬁc mAbs,
which typically required concentrations of N10 μg/ml in both
plasmablast andMBC populations, an amount that is consideredweakly
neutralizing for a DENV-speciﬁc antibody [11,40]. In patients P1 and P4,
MBC-derived complex epitope-speciﬁc mAbs showed a higher sero-
type-speciﬁc neutralizing capacity for DENV-2, the serotype responsible
for the active infection (Fig. 5A), despite similar binding to UV-treated
DENV-1 and/or DENV-3 by ELISA (Fig. 5B). Very potent neutralizing an-
tibodies are usually serotype-speciﬁc [2,12,39–42]. The antibodies test-
ed here were, however, mostly serotype cross-reactive (Fig. 5C),
representing a different yet apparently abundant class of antibodies.
Thus, cross-reactive plasmablasts present during acute disease se-
crete neutralizing E-speciﬁc antibodies, which most likely play an es-
sential role in controlling early viral replication. Cross-reactive MBC-
derived antibodies predominantly recognize complex epitopes, which
are less potent functionally, but still capable of neutralizing the active
infection.
3.4. Distinct Ig Heavy Chain Gene Usage and CDR3 Between Antibodies Iso-
lated From DENV-speciﬁc Memory B Cells and Plasmablasts
Because we observed distinct non-overlapping repertoires in virus-
speciﬁc plasmablasts and MBCs generated after DENV infection, we in-
vestigated whether monoclonal antibodies derived from each of the
two populations could be identiﬁed and discriminated based on their
Ig heavy chain variable region (IgVH) sequences. Plasmablast-derived
mAbs showed a broad usage of VH1 to VH7 genes with the exception
of VH6, indicating that E glycoprotein speciﬁcity was not restricted to
certain VH families (Fig. 6A). For MBC-derived Abs, VH3 and JH4 usage
wasmore dominant, typical of the naïve andMBC repertoires of normal
healthy individuals [43]. Interestingly, some VH gene families with self-
antigen binding potential, includingVH1–69 andVH4–34 [44–46], were
observed speciﬁcally amongst plasmablast-derived DENV-speciﬁc Abs
but not amongst MBC-derived DENV-speciﬁc Abs (Fig. 6A and B).
The length and ﬂexibility of the CDR3 can also contribute signiﬁcant-
ly to antigen binding. We compared the IgH CDR3 length of non-DENV-
binding and DENV-binding MBC- and plasmablast-derived antibodiesFig. 4. Speciﬁcity of antibodies derived from plasmablasts and memory B cells after
secondary infection is markedly different. A) Overview of the assays used to assess the
speciﬁcity of single B cell-derived monoclonal Abs. Abs were characterized into four
groups: EDIII-speciﬁc, E-speciﬁc, prM-speciﬁc, and complex epitope speciﬁc antibodies.
B) DENV-binding Abs as fractions of all Abs tested per patient and per cell type. The
average of DENV-binding Abs across all patients is illustrated for PB-derived Abs and
(MBC)-derived antibodies, with the total number of Abs tested indicated in the center of
the pie charts. C) Percentages of Abs binding to complex epitopes, recombinant E
protein (Rec. E), or prM were deﬁned for plasmablasts (PB) from patients 1 to 7. All E-
speciﬁc Abs of patient 6 bound to EDIII, whereas no EDIII-speciﬁc antibodies were
observed for all other patients and time points analyzed. Binding speciﬁcity was deﬁned
for memory B cells (MBCs) from patients 1 to 4. One MBC-derived Ab could not be
characterized (black bar in Fig. 2C, due to low expression levels (≤ 0.1 μg/ml).
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Fig. 5. E-speciﬁc antibodies have a higher neutralizing capacity compared to complex-epitope-speciﬁc antibodies. A) Neutralizing capacity of 51mAbs representing the different antibody
groups for plasmablasts and MBCs. The patient origin and mAb ID is indicated on the left. The NT50 for PB-derived mAbs was determined for DENV-1,-2 and -3. DENV-4 was not tested
since this serotype is very rare in Singapore. NT50 for the current and the previous serotype of infection (based on the neutralizing proﬁle of the patient plasma) were tested for MBC-
derived mAbs. Each NT50 value represents the mean from three independent experiments. B) Virus particle (UV-DENV) ELISA for complex-epitope-speciﬁc mAbs. C) Cross-reactivity
of antibodies per patient and cell type, assessed by UV-inactivated PEG precipitated virus particle ELISA, rec.E ELISA, immunohistochemistry and western blot assays for DENV-1 to -4.
Abs were grouped based on their ability to bind across all four, three, two or one serotype(s) of DENV in at least one or multiple assays.
185R. Appanna et al. / EBioMedicine 12 (2016) 178–188(sorting strategy in Fig. 1A) in all cells for which a sequence was avail-
able. On average, DENV-binding MBC-derived antibodies had signiﬁ-
cantly longer CDR3 than DENV-binding plasmablast-derived
antibodies and, to a greater extent, non-DENV bindingMBC-derived an-
tibodies (Fig. 6C). Analysis of epitope speciﬁcity indicated that complex
epitope-speciﬁc and prM-speciﬁc antibodies seemed to account for the
longer CDR3 sequences of DENV-speciﬁc MBCs compared to
plasmablasts and non-DENV-speciﬁc MBCs (Fig. 6D). CDR3s of prM-
speciﬁc antibodies also contained signiﬁcantly more neutral non-polar
amino acids than E-speciﬁc Abs (Fig. 6E).
The immediate appearance of plasmablasts following infection indi-
cates that they are unlikely to participate in a germinal center reactionbefore their differentiation into antibody-secreting cells. We hypothe-
sized thatMBCs therefore underwent a (primary or secondary) GC reac-
tion before their appearance in the blood during early convalescence.
However, both memory B cells and plasmablasts showed similar levels
of nucleotide mutations in the heavy chain variable region (Fig. 6F)
and in the CDR3 (data not shown) compared to reference germline se-
quences (the international ImMunoGeneTics information system®
http://www.imgt.org), and also showed similar levels of nucleotide ad-
ditions (Fig. 4G). Similarly, a comparison of mutations in frame 1, 2, and
3 versus CDR1 and CDR2 showed that all Abs, independent of speciﬁcity
and plasmablast or MBC origin, had comparable numbers of silent ver-
sus replacement mutations (Supplementary Fig. 3 online).
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Fig. 6. DENV-binding antibodies derived from PB and memory B cells use distinct VH genes but show similar mutation rates. A–B) VH gene family usage for epitope-speciﬁc antibodies
derived from plasmablasts (PB) (A) and memory B cells (MBCs) (B). Ab speciﬁcity is indicated with different colors, and the numbers of Abs per gene family is indicated on the y axes.
Signiﬁcant differences between PB and MBCs were calculated with a Fisher's Exact test: prM: p = 1.00, Complex epitope: p = 0.298, Rec.E: p = 0.022. C) Comparison of the CDR3
length of all plasmablasts (primary and secondary infection; n = 603) with the CDR3 length of DENV-binding MBCs (n = 245) and DENV-non-binding MBCs (n = 163). P b 0.0001
(one-way ANOVA with Tukey's multiple comparison test). D) CDR3 lengths of plasmablast (PB) and MBC-derived Abs across Ab speciﬁcities. E) Content of neutral non-polar amino
acids (AA) in CDR3 sequences from prM-speciﬁc Abs compared to CDR3 sequences from rec. E-speciﬁc Abs. F) VH nucleotide mutation frequencies of plasmablast-derived Abs and
MBC-derived Abs of different speciﬁcity. A one-way ANOVA analysis comparing all ﬁve groups of Abs (both plasmablast and MBC-derived) showed no signiﬁcant differences between
plasmablasts and MBCs. G) Number of CDR3 nucleotide (N) additions for all Ab groups. For scatter plots each dot represents one Ab and horizontal lines indicate the means. Whiskers
in the box and whisker graphs indicate min to max values.
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187R. Appanna et al. / EBioMedicine 12 (2016) 178–188In conclusion, plasmablasts and DENV-speciﬁc MBCs differed signif-
icantly in their IgVH gene usage and CDR3 length, but not in their muta-
tion rates. Therefore, despite being clonally unrelated, both populations
appear to have undergone a similar level of afﬁnity maturation and
selection.
4. Discussion
Immunememory allows for the efﬁcient activation and expansion of
B cells during recall responses. It has longbeen established that a recall B
cell response involves rapid generation of plasmablasts and a temporal-
ly delayed formation of germinal centers. It is less clear, however, which
B cells enter each path, and how the plasmablast and classicalmemory B
cell population is related during acute stages of infection. We ﬁnd here
that plasmablast and memory B cell formation after DENV re-infection
involves clonally distinct B cells. The clonally related sequences were
all of the IgM isotype and could represent B cells that bound to DENV
with low afﬁnity and that were enriched during the sorting with ﬂuo-
rescently labeled virus. This binding could be cognate or via heparan
sulfate, which is a receptor for DENV. Although DENV-binding cells
were sorted from the CD27+memory B cell population (Fig. S1)we can-
not exclude that fewnaïve CD27− naïve B cellswere also included in the
memory gate. The accumulation of IgM+ cells in the DENV-binding but
not the control memory B cell pool (Fig. 2E) further points to an enrich-
ment of low afﬁnity IgM B cells. We did not have a pentameric IgM ex-
pression system and were not able to verify the binding of the MBC-
DENV–derived IgM antibodies. A role of IgMMBCs inmaintainingmem-
ory over prolonged periods of time and the capacity of IgMMBCs to re-
enter germinal centers is intriguing [15,16] butwill have to be studied in
more detail in the context of dengue.
Of note, 40–60% of the clonedmABs from sorted IgGMBC-DENV cells
were found to speciﬁcally bind to DENV (Fig. 4B) and this validated our
sorting strategy. None of the IgG MBC CDR3 sequences, however, were
shared with the PB repertoire.
We observed that memory B cell-derived, complex epitope-speciﬁc
antibodies were less neutralizing than plasmablast-derived, E-speciﬁc
Abs. This was surprising because a number of MBC-derived complex-
speciﬁc antibodies are described in the literature to be potent neutral-
izers [2,41,42,47]. We assume that the potent neutralizers previously
described, which were all serotype-speciﬁc, are rare in the memory
pool and our sampling size was not large enough to pick them up. In
our experiments, the majority of the DENV-speciﬁc isolated MBCs
were cross-reactive, butweakly neutralizing. The sorting strategy focus-
ing on DENV-3-binding B cells likely created a bias towards cross-reac-
tive B cells. Nevertheless, some cross-reactive MBCs did show a higher
neutralizing capacity for the recent infecting DENV serotype (DENV-2
for patients P1 and P4 with DENV-2-speciﬁc neutralization, Fig.4A). Al-
though having a low neutralizing capacity, the large proportion of MBCs
that express BCRs speciﬁc for virus particles could play an important
role as antigen-presenting cells during acute viral infection.
It is curious that only E-protein speciﬁc, mostly IgG+ MBCs seemed
to participate in the plasmablast response during re-infection while
serum levels of prM and NS1-speciﬁc Abs also increased during acute
disease (Table 1). PrM and NS1-speciﬁc MBCs might differentiate into
antibody-secreting cells upon infection without circulating in the
blood as plasmablasts. MBCs might also become long-lived plasma
cells that are retained in the bone marrow and in other secondary lym-
phoid organs [48], accounting for the pre-existing antibodies early after
fever onset (Table 1).
The dynamics of immunememory re-activation is of special interest
for dengue virus infection where original antigenic sin is a prominent
phenomenon that complicates efﬁcacious vaccination against all four
serotypes. In this context, it is important to understand the origin of rap-
idly responding plasmablasts as the effector cells of antibody-mediated
original antigenic sin. Determining the particular MBC subset [28] that
they are derived from is complicated because the gene expressionproﬁle and surface marker expression of MBCs change upon differenti-
ation into plasmablasts. While our data do not solve the question about
the origin of plasmablasts during acute dengue infection our ﬁndings
have two main implications: a) After vaccination, plasmablasts and
MBCs could be analyzed anddifferentiated based on their distinct reper-
toires, providing a potential biomarker to compare the responses be-
tween vaccine-induced and natural infections and to analyze
responses to new vaccine candidates. B) The plasmablast response
and the ensuing temporary burst of E-protein-speciﬁc antibodies in
the plasma may not be a useful readout for long-term immune protec-
tion in dengue as it is only representative of a small fraction of the
total memory B cell pool.
Memory B cell-derived antibodies isolated here and those reported
previously by others [11,12,14] bind to E, prM, NS1 and this spectrum
is more in line with the speciﬁcity serum antibodies that are produced
after re-infection and during early convalescence (Table 1). Whether
the re-activation of these memory B cells as antibody-secreting cells
or as antigen-presenting cells, however, is crucial for protection in den-
gue patients remains to be studied. Analysis of both the acute phase
plasmablasts and memory B cells will be crucial to start to understand
the biological relevance of different levels of B cellmemory that are gen-
erated after dengue infection.
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